Clinical Trials Sponsored by Arcellx, Inc.

Total 35417 results

Arcellx, Inc.

Recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Axcella Health, Inc

Terminated

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

Hepatic Encephalopathy

Spain, United States, Canada, Italy, Hungary, Poland, United Kingdom
Axcella Health, Inc

Completed

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Sickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease | Sickle Cell Disorders

United States
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Axcella Health, Inc

Completed

Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

United Kingdom
Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Hepatic Insufficiency

United States
Axcella Health, Inc

Terminated

Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD

United Kingdom
Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD

United States
AcelRx Pharmaceuticals, Inc.

Completed

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Healthy

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Acute Moderate-to-severe Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Post-Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Effect of Delivery Route on PK of Sufentanil NanoTab

Pharmacokinetics

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Post-Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Plasma Concentrations

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Major Upper or Lower Abdominal Surgery

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Pain | Cancer

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement (ARX-F01)

Post Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Post-Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Pharmacokinetics

United States
AcelRx Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Acute Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Pain | Anxiety | Sedation

United States
AcelRx Pharmaceuticals, Inc.

Completed

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Moderate-to-severe Acute Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Post Operative Pain

United States
AcelRx Pharmaceuticals, Inc.

Completed

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

Pain, Postoperative

United States
Kite, A Gilead Company
Arcellx, Inc.

Recruiting

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
Kite, A Gilead Company
Arcellx, Inc.

Recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) (iMMagine-1)

Multiple Myeloma

United States
McMaster University
Axcella Health, Inc

Completed

Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization

Muscle Atrophy

Canada
Ardelyx

Completed

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia (OPTIMIZE)

Hyperphosphatemia | Chronic Kidney Disease Requiring Chronic Dialysis

United States
Ardelyx

Completed

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Hyperphosphatemia

United States
Ardelyx

Completed

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Hyperphosphatemia

United States, Poland, United Kingdom, Slovakia
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Healthy Volunteers

United States
Ardelyx

Completed

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Healthy Volunteers Food Interaction Study

United States
Ardelyx

Completed

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

Healthy Volunteers

United States
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Ardelyx

Completed

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Hyperphosphatemia

United States
Ardelyx

Completed

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP (NORMALIZE)

End Stage Renal Disease | Hyperphosphatemia

United States
Ardelyx

Completed

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Hyperphosphatemia

United States
Ardelyx

Completed

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Recruiting

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

Lactation

United States
Ardelyx

Enrolling by invitation

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Ardelyx

Completed

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia (Redukx)

Hyperkalemia

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Terminated

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Hyperkalemia

United States
Ardelyx

Completed

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Healthy Volunteers

United Kingdom
Ardelyx
AstraZeneca

Completed

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

Healthy

United States

3

Subscribe